JPRN-UMIN000008203已完成2 期
Phase2 study of perioperative XELOX in patients with locally-advanced lower rectal cancer - Phase2 study of perioperative XELOX in patients with locally-advanced lower rectal cancer
Multicenter Study Group of Osaka (MCSGO), Colorectal Cancer Treatment Group0 个研究点目标入组 44 人开始时间: 2012年6月19日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 25years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Need to drain malignant coelomic fluid. 2) With distant metastases 3) Multiple primary cancer within 5years 4) Symptomatic or asymptomatic but treated heart disease 5) History of the serious hypersensitivity for Fluorouracil, platinum compound and levofolinate calcium 6) History of adverse events related to DPD loss 7) Uncontrolled Diarrhea 8) Peripheral neuropathy(Grade1<=) 9) Uncontrolled infection 10) Pregnant women, possibly pregnant women, wishing to become pregnant, and nursing mothers 11) No intention to practice birth control 12) Previously treated with oxaliplatin 13) Other conditions not suitable for this study
研究者
相似试验
招募中
2 期
Phase II study of XELOX as perioperative chemotherapy for locally advanced rectal cancerocally advanced rectal cancerJPRN-UMIN000008316agoya Surgical Oncology Group60
已完成
不适用
Pilot study of preoperative chemotherapy of XELOX+ Bevacizumab in patients with locally-advanced lower rectal cancerRectal cancerJPRN-UMIN000003219Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group20
招募中
1 期
Phase I/II study of preoperative treatment with XELOXIRI(CPT-11, L-OHP, capecitabine) with Cetuximab in patients with RAS wild type-advanced colorectal cancerJPRN-UMIN000032784Sapporo Medical University School of Medicine Department of Surgery, Surgical Oncology and Science48
已完成
不适用
The Efficacy Study of Neoadjuvant Xelox in Patients with Locally Advanced Lower Rectal CancerJPRN-UMIN000007087Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University30
已完成
2 期
A randomized phase II study of XELOX plus Bevacizumab versus XELIRI plus Bevacizumab for advanced colorectal cancer with or without mitochondrial transcription factor A (mtTFA) expression.nresectable advanced/recurrent colorectal cancerJPRN-UMIN000005060Fukuoka University Hospital100